We experienced technical difficulties with capturing this session, so we are unable to make the session available for on-demand access. We apologize for the inconvenience.
Canine hemangiosarcoma (HSA) is an aggressive cancer with a high proclivity for metastasis and poor responsiveness to chemotherapy. The Ethos-Precision Medicine Umbrella Study for Hemangiosarcoma (EPUSH) clinical trial for dogs with splenic HSA seeks to identify novel treatment approaches that deliver meaningful clinical benefit in dogs with HSA, genomic biomarkers of prognosis, and biomarker-drug matches associated with exceptional drug response that provide the basis for subsequent clinical trials with optimized drug combinations that seek to deliver curative outcomes for HSA. The objectives of these lead-in studies were to establish the safety/tolerability and pharmacokinetic parameters for 1) oral paclitaxol (Oraxol), 2) sorafenib, and 3) a novel oil-based formulation of rapamycin in cancer-bearing dogs prior to their use in EPUSH.
Learning Objectives:
Understand the mechanisms of action of the anticancer agents Oraxol, Sorafenib, and Rapamycin.
Define the pharmacokinetic parameters associated with drug exposure of sorafenib and a novel, oil-based formulation of rapamycin in tumor-bearing dogs.
Summarize the tolerability and dosing schedules for oraxol, sorafenib, and a novel, oil-based formulation of rapamycin in dogs with spontaneous cancer.
.png)
